Will Comparative Effectiveness Drive Biopharma Competition?
By Mari Serebrov
Wednesday, July 6, 2011
Comparative-effectiveness research (CER) is a C-suite issue that is already reshaping how some biotechs do business.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.